[Evaluation of the results of the treatment of patients with subacute sclerosing panencephalitis with TFX-Polfa].
The authors report the results of a trial of treatment of patients with SSPE with the preparation TFX-POLFA given together with isoprinosine and amantadine to 13 children for 12 weeks, and to 7 for 6 weeks. The results of clinical and immunological treatment were compared with those in a group of 10 patients with SSPE receiving only isoprinosine and amantadine. In both groups a steady deterioration of the neurological status was observed in about half the cases. No significant effect of TFX was observed on the immune reactivity. During the treatment with TFX the per cent of lymphocytes forming early E rosettes rose.
Vainiene
M
M
Sobczyk
W
W
D000293:Adolescent; D000547:Amantadine / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007542:Inosine Pranobex / Q000627:therapeutic use; D008297:Male; D013344:Subacute Sclerosing Panencephalitis / Q000188:drug therapy*; D013949:Thymus Extracts / Q000627:therapeutic use*
C019108:TFX; D013949:Thymus Extracts; D000547:Amantadine; D007542:Inosine Pranobex
Ocena wyników leczenia preparatem TFX-Polfa chorych z podostrym stwardniajacym zapaleniem mózgu.